Head-to-head evidence
FB-101 vs Risvodetinib (IkT-148009)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: c-Abl · full Parkinson's Disease pipeline
FB-101
Developed by 1ST Biotherapeutics, Inc.
NCT04165837 · Phase 1 · completed
Participants were randomized to FB-101 or placebo with blinding of participants, care providers, and investigators, but the primary endpoint is adverse-event incidence in healthy volunteers rather than a Parkinson's disease outcome, and no results have been posted.
Risvodetinib (IkT-148009)
Developed by ABLi Therapeutics, Inc. and partners
NCT05424276 · Phase 2 · completed
The trial was well designed - randomized, blinded, and placebo-controlled with roughly 33-35 patients per arm - but its designated primary endpoint was adverse-event incidence rather than a disease-related clinical outcome, and no statistical comparison across arms was reported for that primary endpoint (event rates were similar across all four groups: 54-64%). The efficacy-related measures (MDS-UPDRS, PDQ-39, etc.) were only secondary and the study was explicitly stated as not powered to detect efficacy differences, with results showing no consistent separation from placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: FB-101's landscape · Risvodetinib (IkT-148009)'s landscape